VOL.: 26 (1981) (p. 349)
Vinblastine sulphate can induce teratogenic effects in several animal species and embryolethality at doses nontoxic to the mother. On the basis of the available data, this compound cannot be considered to be mutagenic.
The available data are insufficient to evaluate its teratogenic effects in humans. No data on the mutagenicity or chromosomal effects of vinblastine sulphate in humans were available.
Vinblastine sulphate, mainly in combination therapy, has been associated in case reports with the subsequent development of leukaemias. The only epidemiological study was small and of short duration and showed no excess of subsequent neoplasms in patients treated with a regimen including vinblastine sulphate, adriamycin, bleomycin and dacarbazine.
There is no evidence currently available to indicate that vinblastine sulphate is carcinogenic to humans, but the compound has not been extensively investigated.
Subsequent evaluation: Suppl. 7 (1987)
See Also: Toxicological Abbreviations Vinblastine Sulphate (IARC Summary & Evaluation, Supplement7, 1987)